Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases
- PMID: 29156910
- DOI: 10.21037/apm.2017.09.01
Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases
Abstract
Background: Patients with bone metastases undergoing palliative radiation therapy (RT) may experience changes in both the functional and symptomatic aspects of quality of life (QOL). The European Organization of Cancer Research and Treatment (EORTC) QOL Questionnaire Core-15 Palliative (QLQ-C15-PAL) is a validated questionnaire employed to assess QOL specifically in palliative patients. Our study aimed to identify single-nucleotide variant (SNV) genetic biomarkers associated with changes in QOL and pain.
Methods: Fifty-two patients who received a single 8-Gy RT for painful bone metastases completed the EORTC QOL-C15-PAL questionnaire prior to randomization and at 42-day post RT. Saliva samples obtained at day of RT were sequenced, and SNVs from genes involved in inflammation, radiation response, immune response, DNA damage, or QOL were assessed for association with changes in global QOL or the pain scale items using the Cochran-Armitage trend test. The penalized LASSO method with minimum Bayesian information criterion was used to select a multi-SNV model out of significant SNVs (P<0.005) and to produce prognostic scores for patients that categorized them into risk groups of low, middle, and high.
Results: The multivariable model predicting global QOL included 14 SNVs, of which HS1BP3 rs35579164 G:C and ABCA1 rs2230805 C>T had the largest positive and negative effect sizes, respectively (HS1BP3: 8.21, ABCA1: -3.44). The model for the response of QOL pain item included 8 SNVs, of which PLAUR rs4760 A>G and ELAC2rs11545302 had the largest positive and negative effect sizes, respectively (PLAUR: 5.23; ELAC: -3.84). The patients' risk groups were highly predictive of QOL response (P<0.0001) and pain item response (P<0.0001). In logistic regression analysis accounting for baseline factors of gender and primary cancer site, the global QOL risk group predicts pain response after RT [OR: 2.1, 95% confidence interval (CI): 1.2-3.9, P=0.015], but the QOL pain item risk group did not (OR: 0.93; 95% CI: 0.5-1.6, P=0.79). The multi-SNVs model included SNVs from genes involved in metabolism, membrane transport, cell cycle control, ciliary structure, and gene expression regulation.
Conclusions: SNVs were significantly associated with changes in global QOL of global domain and pain item in patients with bone metastases. Identification of genetic biomarkers predictive of QOL items may allow patients and health care providers anticipate and better address the needs of the palliative cancer patient population.
Keywords: Genetic biomarker; cancer symptoms; palliative radiotherapy; quality of life (QOL); single nucleotide variant.
Similar articles
-
Genetic biomarkers associated with pain flare and dexamethasone response following palliative radiotherapy in patients with painful bone metastases.Ann Palliat Med. 2017 Dec;6(Suppl 2):S240-S247. doi: 10.21037/apm.2017.09.04. Epub 2017 Sep 20. Ann Palliat Med. 2017. PMID: 29156912 Clinical Trial.
-
Genetic biomarkers associated with response to palliative radiotherapy in patients with painful bone metastases.Ann Palliat Med. 2017 Dec;6(Suppl 2):S233-S239. doi: 10.21037/apm.2017.09.03. Epub 2017 Oct 10. Ann Palliat Med. 2017. PMID: 29156909 Clinical Trial.
-
Gender differences in pain and patient reported outcomes: a secondary analysis of the NCIC CTG SC. 23 randomized trial.Ann Palliat Med. 2017 Dec;6(Suppl 2):S185-S194. doi: 10.21037/apm.2017.08.12. Epub 2017 Aug 29. Ann Palliat Med. 2017. PMID: 29156903 Clinical Trial.
-
Evaluation of quality of life outcomes following palliative radiotherapy in bone metastases: A literature review.J BUON. 2019 Sep-Oct;24(5):1747-1760. J BUON. 2019. PMID: 31786834 Review.
-
Re-treatment of bone metastases for pain control: 2023 ASTRO education panel.Ann Palliat Med. 2024 Jul;13(4):1154-1160. doi: 10.21037/apm-24-15. Epub 2024 Jun 12. Ann Palliat Med. 2024. PMID: 38902990 Review.
Cited by
-
Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain.J Exp Med. 2021 Jul 5;218(7):e20202059. doi: 10.1084/jem.20202059. Epub 2021 May 10. J Exp Med. 2021. PMID: 33970188 Free PMC article.
-
Genetic Variants Associated with Cancer Pain and Response to Opioid Analgesics: Implications for Precision Pain Management.Semin Oncol Nurs. 2019 Jun;35(3):291-299. doi: 10.1016/j.soncn.2019.04.011. Epub 2019 May 10. Semin Oncol Nurs. 2019. PMID: 31085105 Free PMC article. Review.
-
Personalized Radiation Therapy in Cancer Pain Management.Cancers (Basel). 2019 Mar 19;11(3):390. doi: 10.3390/cancers11030390. Cancers (Basel). 2019. PMID: 30893954 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical